Proteostasis Therapeutics, Inc. (PTI) insiders have most recently took part in a trading activity. On Dec 18, 2017 Barrett M James, Director, 10% Owner bought 2,000,000 shares having total worth of $10,000,000 at the price of $5 per share, following the transaction a total of 5,554,610 shares owned by Barrett M James.
On the same day, New Enterprise Associates 12, Limited Partnership, 10% Owner bought 2,000,000 shares having total worth of $10,000,000 at the price of $5 per share, following the transaction a total of 5,554,610 shares owned by New Enterprise Associates 12, Limited Partnership.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 sell activities .Furthermore, over the past 12 months , the stock was traded 8 times by insiders. In 8 of these trades, the insider was a seller .
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Proteostasis Therapeutics, Inc. (PTI) traded down 10.42% on Dec 18, 2017, hitting $4.47. 1,495,354 shares of the company’s stock traded hands. Proteostasis Therapeutics, Inc. has a 52 week low of $1.56 and a 52 week high of $19.41. The company’s market cap is $0 million.
Proteostasis Therapeutics, Inc. (PTI) last announced its earnings results on Nov 14, 2017. The company reported -0.56 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.72 by $0.16. The company had revenue of $2 million for the quarter, compared to the consensus estimate of $1 million. During the same quarter in the previous year, the company posted -0.54 earnings per share. The company’s revenue for the quarter was down 10% on a year-over-year basis.
|earnings per share||-0.56||-0.38||-0.54||-0.47|
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018